Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101, a CAR-T Therapy Predominantly … – GlobeNewswire (press release)
|
Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101, a CAR–T Therapy Predominantly …
GlobeNewswire (press release) SAN DIEGO, Oct. 05, 2017 (GLOBE NEWSWIRE) — Poseida Therapeutics Inc. (“Poseida”), a San Diego-based clinical-stage company translating best-in-class gene therapy technologies into lifesaving cell therapies, today presented preclinical data on … |
